Neutralizing antibody (nAb) responses which target the Env of HIV-1 and block viral entry develop in most HIV-1 infected individuals, reaching detectable levels within a few months of infection when measured against the autologous Env [1],[2],[3],[4]. The gene discussed is ERVW-1; the disease is infection.